Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer

Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. Laboratory data from seven patients with pancr...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2015-01, Vol.35 (1), p.555-562
Main Authors: Takakura, Kazuki, Koido, Shigeo, Kan, Shin, Yoshida, Kosaku, Mori, Masako, Hirano, Yuta, Ito, Zensho, Kobayashi, Hiroko, Takami, Shinichiro, Matsumoto, Yoshihiro, Kajihara, Mikio, Misawa, Takeyuki, Okamoto, Masato, Sugiyama, Haruo, Homma, Sadamu, Ohkusa, Toshifumi, Tajiri, Hisao
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Adenocarcinoma - mortality
Adenocarcinoma - secondary
Adenocarcinoma - therapy
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Biomarkers, Tumor
Cancer Vaccines - administration & dosage
Cancer Vaccines - immunology
Cells, Cultured
Combined Modality Therapy
Cytokines - blood
Dendritic Cells - immunology
Dendritic Cells - transplantation
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Female
Histocompatibility Antigens Class I - immunology
Histocompatibility Antigens Class II - immunology
Humans
Lymphocyte Count
Male
Middle Aged
Neutrophils - immunology
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - therapy
Peptide Fragments - immunology
Prognosis
Treatment Outcome
Vaccination
WT1 Proteins - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry. The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders. An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy.
ISSN:0250-7005
1791-7530